Sonic Incytes Medical Corp. announced a multi-year partnership with Madrigal Pharmaceuticals on Thursday to expand point-of-care liver assessment for patients with or at risk for metabolic dysfunction-associated steatohepatitis (MASH), the companies said in a joint release.
The collaboration centers on Sonic Incytes’ Velacur ONE platform, an AI-guided ultrasound elastography device that measures liver stiffness, attenuation and a proprietary metric called Velacur Determined Fat Fraction (VDFF). The device received initial U.S. Food and Drug Administration 510(k) clearance in 2020. The companies said they will initially target gastroenterology, hepatology and endocrinology practices to integrate non-invasive testing into routine clinical workflows.
“MASH remains significantly underdiagnosed, and too many patients are missed or identified only after their disease has advanced,” said Barry Allen, president and chief executive of Sonic Incytes. “We look forward to working with Madrigal to help clinicians deliver non-invasive liver assessments to the patients who need them, where they need them.”
An estimated 80–100 million U.S. adults have metabolic dysfunction-associated steatotic liver disease (MASLD), and an estimated 15–20 million have MASH, according to figures cited in the release. As many as 90 percent of MASH cases remain undiagnosed. Left untreated, MASH can progress to cirrhosis, liver failure, liver cancer, transplantation or death.
Technology designed for broader patient populations
Velacur ONE uses 3D S-WAVE technology, which the company says provides approximately 30 times greater sampling volume and up to twice the measurement depth of traditional vibration-controlled transient elastography (VCTE). The platform combines that sampling capability with AI guidance to support consistent, reproducible assessments across a broad range of patients, including those with elevated body mass index.

The company said 3D S-WAVE has shown strong agreement with magnetic resonance elastography (MRE), and VDFF has shown strong correlation with MRI proton density fat fraction, the non-invasive gold standard for measuring liver fat. The device has also been validated against liver biopsy.
Shifting assessment to the point of care
Current guidelines recommend non-invasive testing, including elastography, to assess liver fibrosis. Limited access to elastography in community settings can delay evaluation and follow-up. Because Velacur ONE delivers real-time results during a clinic visit, liver health can be assessed without a separate referral, the companies said. Results help clinicians decide on next steps, including further evaluation or referral when appropriate. Treatment decisions remain with the clinician and patient.
“Clinicians need practical tools that fit their existing workflows,” Allen said. “Madrigal has helped transform what is possible for people living with MASH. Together, we want to make objective liver assessment easy to access, so more patients can be identified and evaluated at the point of care.”
The partnership reflects a broader shift toward treating liver health as part of comprehensive metabolic care. By combining Sonic Incytes’ point-of-care technology with Madrigal’s experience in MASH therapeutics — the company has an approved therapy for MASH and a pipeline of investigational candidates — the companies aim to support clinicians building more systematic approaches to identifying and assessing at-risk patients.
Madrigal Pharmaceuticals, based in Pennsylvania, is a biopharmaceutical company focused on delivering novel therapeutics for MASH. Sonic Incytes, based in Vancouver, British Columbia, develops the Velacur point-of-care liver assessment platform.
MASH prevalence and Velacur ONE technology differences explained
What is MASH and how common is it?
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of fatty liver disease characterized by inflammation and liver cell damage. The release cites estimates that 15 million to 20 million U.S. adults have MASH, with up to 90 percent of cases undiagnosed.
How does Velacur ONE differ from traditional elastography?
Velacur ONE combines AI guidance with 3D S-WAVE technology, which the company says provides roughly 30 times the sampling volume and up to twice the measurement depth of vibration-controlled transient elastography (VCTE). It also measures a proprietary fat metric, VDFF, which correlates with MRI proton density fat fraction.
Where will the partnership focus first?
The companies said they will initially expand use of non-invasive tests in gastroenterology, hepatology and endocrinology settings.
Does the device replace a liver biopsy?
The release states Velacur has been validated against liver biopsy and supports clinical evaluation, but treatment decisions remain with the clinician and patient. It is positioned as a non-invasive assessment tool to aid earlier identification and risk stratification.
Worth a look